These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 22016628)
1. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Rodrigues AC; Perin PM; Purim SG; Silbiger VN; Genvigir FD; Willrich MA; Arazi SS; Luchessi AD; Hirata MH; Bernik MM; Dorea EL; Santos C; Faludi AA; Bertolami MC; Salas A; Freire A; Lareu MV; Phillips C; Porras-Hurtado L; Fondevila M; Carracedo A; Hirata RD Int J Mol Sci; 2011; 12(9):5815-27. PubMed ID: 22016628 [TBL] [Abstract][Full Text] [Related]
2. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738 [TBL] [Abstract][Full Text] [Related]
3. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570 [TBL] [Abstract][Full Text] [Related]
4. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia. Shabana MF; Mishriki AA; Issac MS; Bakhoum SW Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857 [TBL] [Abstract][Full Text] [Related]
5. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272 [TBL] [Abstract][Full Text] [Related]
6. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. de Keyser CE; Peters BJ; Becker ML; Visser LE; Uitterlinden AG; Klungel OH; Verstuyft C; Hofman A; Maitland-van der Zee AH; Stricker BH Pharmacogenet Genomics; 2014 Jan; 24(1):43-51. PubMed ID: 24263182 [TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492 [TBL] [Abstract][Full Text] [Related]
8. SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians. Sortica VA; Fiegenbaum M; Lima LO; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH Clin Chem Lab Med; 2012 Mar; 50(3):441-8. PubMed ID: 22505549 [TBL] [Abstract][Full Text] [Related]
9. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Pasanen MK; Backman JT; Neuvonen PJ; Niemi M Eur J Clin Pharmacol; 2006 Jun; 62(6):409-15. PubMed ID: 16758257 [TBL] [Abstract][Full Text] [Related]
10. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers. Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210 [TBL] [Abstract][Full Text] [Related]